Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.
Benjamin L. Schlechter, MD
Advertisement
Articles by Benjamin L. Schlechter, MD
Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.
Advertisement
Latest Updated Articles
Uptake of Nononcology Gene Therapy Remains Slow in HematologyPublished: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLDPublished: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 DataPublished: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell TherapyPublished: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMDPublished: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of VisionPublished: May 18th 2023 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Nanoscope Nabs RMAT Designation for Retinitis Pigmentosa Gene Therapy MCO-010
2
CGTLive®’s Weekly Rewind – September 5, 2025
3
Preclinical Evidence for PH1 Gene Therapy
4
Robert Alexander Wesselhoeft, PhD, on the Therapeutic Potential of Circular RNA
5
